Controllable transgene expression systems are indispensable tools for the production of animal models of disease to investigate protein functions at defined periods. However, in nonhuman primates that share genetic, physiological, and morphological similarities with humans, genetic modification techniques have not been well established; therefore, the establishment of novel transgenic models with controllable transgene expression systems will be valuable tools to understand pathological mechanism of human disease. In the present study, we successfully generated transgenic marmosets using a tetracyclin-inducible transgene expression (tet-on) system as a neurodegenerative disease model. The mutant human ataxin 3 gene controlled by the tet-on system was introduced into marmoset embryos via lentiviral transduction, and 34 transgene-introduced embryos were transferred into the uteri of surrogate mothers. Seven live offspring (TET1-7) were obtained, of which four were transgenic. Fibroblasts from TET1 and 3 revealed that inducible transgene expression had occurred after treatment with 10 μg/mL of doxycycline, while treatment with doxycycline via drinking water resulted in 1.7-to 1.8-fold inducible transgene expression compared with before treatment. One transgenic second-generation offspring (TET3-3) was obtained from TET3, and doxycycline-inducible transgene expression in its fibroblasts showed that TET3-3 maintained a high transgene expression level that matched its parent. In conclusion, we established a Transgenic marmoset production with tet-on system, 2017, Vol. 97, No. 5 773 novel transgenic marmoset line carrying the mutant human ataxin 3 gene controlled by the tet-on system. The development of nonhuman primate models with controllable transgene expression systems will be useful for the identification of disease biomarkers and evaluation of the efficacy and metabolic profiles of therapeutic candidates.
Introduction
Nonhuman primates have contributed to medical science as valuable models of human disease because of their genetic, physiological, and morphological similarities to humans. They are particularly valuable in research into neurodegenerative diseases because of their longer lifespans and larger brain size compared with those of rodents. The long lifespans enable the development of pathologies that clinically mimic human neurodegenerative diseases, while their larger brain size permits imaging analyses such as magnetic resonance imaging or positron-emission tomography to be carried out. Transgenic animal models of human disease are powerful tools to understand pathological mechanism because they display clinically relevant symptoms and provide novel insights into intrinsic genetic factors underlying disease. Hence, the production of transgenic nonhuman primates is desirable to model various human diseases including neurodegenerative diseases.
The first transgenic nonhuman primate model for neurodegenerative disease was reported by Yang et al. and expressed the polyglutamine-expanded huntingtin gene under a ubiquitously expressed promoter [1] . Although it resulted in hallmark features of Huntington's disease (HD) being observed in the brain of several transgenic monkeys together with other symptoms, these were too severe for the monkeys to survive into adulthood. Recently, we generated a transgenic marmoset model for spinocerabellar ataxia type 3, also known as Machado-Joseph disease (MJD) [2] , and used the cytomegalovirus (CMV) promoter to induce high transgene expression in the generation of a symptomatic marmoset model [3] . However, our transgenic marmosets showed a high rate of fetal death, juvenile disease onset, and rapid disease progression that are unusual in human patients with MJD, and F1 offspring were difficult to obtain by natural mating. It appears that although ubiquitously expressed promoters induce strong transgene expression, they also lead to clinically irrelevant symptoms and abnormalities in fetal development. Therefore, controlling transgene expression is one of the most important factors in the development of animal models of human disease.
Tetracycline-controllable transgene expression systems, originally reported in 1995 [4] , have been widely used in a variety of mammalian cell lines and in whole animals [5] . Recently, a modified reverse tetracycline-controlled transactivator protein (rtTA) was used to produce a range of transgenic animals including pigs [6] , dogs [7] , and chickens [8] . In these reports, rtTA strains and transactivator response element (TRE) strains were crossed to produce transgenecontrollable transgenic animals. Jin et al generated transgenic pigs using a single vector including an rtTA and TRE-controlled transgene, demonstrating the feasibility of this system as an efficient and reliable means of obtaining long-lived and large animals [9] . The tetracycline-controllable transgene expression system also yielded new information about neurodegeneration. For example, a transgenic mouse model of HD produced using this system demonstrated neuronal inclusions, characteristic neuropathology, and progressive motor dysfunction [10] . The blocking of transgene expression led to the disappearance of inclusions and amelioration of the behavioral phenotype, raising the possibility that neurodegenerative disease may be reversible. A tetracycline-controllable transgene expression system induced-transgenic mouse model of MJD has also been produced, and symptomatic mice in an early disease state were indistinguishable from wild-type mice 5 months after switching off transgene expression, suggesting that reducing the production of pathogenic ataxin 3 may be a promising approach to treat MJD [11] . However, transgenic nonhuman primate models carrying the tetracyclin-inducible transgene expression (tet-on) system have not been reported, and the plasticity of neurodegeneration in primates remains unknown.
Here, we generated a transgenic marmoset line carrying the mutant human ataxin 3 gene controlled by the tet-on system in a single vector. The offspring of these transgenic marmosets also showed controllable transgene expression with doxycycline treatment. Our method of developing transgenic animal models using the tet-on system will provide novel information about various neurodegenerative diseases.
Materials and methods

Ethics
All animal experiments were approved by the Ethics Committee for Primate Research of the National Center of Neurology and Psychiatry in Japan. All experiments were conducted in accordance with institutional guidelines and the National Research Council's Guide for Care and Use of Laboratory Animals.
Construction of the mutant ataxin 3-120Q vector controlled by the tet-on system
The full-length human ataxin 3 gene (NG 008198) with 120 CAGs (ataxin 3-120Q) was inserted downstream of the TRE region of a self-inactivating lentiviral vector (RIKEN, Tsukuba, Japan). CAA triplets were inserted every 30 repeats of CAGs to avoid CAG repeat length mutations. A marker gene encoding the Kusabira orange (KO) protein and rtTA sequence was linked by a self-cleaving 2A peptide (2A) sequence, and the resultant constructs were driven by the CMV promoter ( Figure 1 ).
Lentiviral vector preparation and transduction
Lentiviral vectors were produced as previously described [3] . Briefly, lentiviruses were generated by co-transfection of lentiviral vectors coding for TRE-ataxin 3-120Q-CMV-KO-2A-rtTA (Figure 1) , pCAG-HIVgp (RIKEN), and pCMV-VSV-G (RIKEN) into 293FT packaging cells (R70007, Thermo Fisher Scientific). The medium containing viral particles was spun at 50 000 × g for 2 h at 4
• C, and the viral pellet was resuspended in Blast Assist medium (12150010, ORIGIO, Denmark) in 1/1000 of the volume of the original lentiviral vector supernatant. High-titer (1 × 108-1011 transducing units per mL) viruses were used for subsequent gene transfer. Four-cell to morula stage embryos were placed in M2 medium (M7167, Sigma) supplemented with 0.1 M sucrose, and the virus was injected into the perivitelline space using an Eppendorf FemtoJet Express microinjector (Eppendorf).
Embryo collection and transfer
To determine the ovarian cycle, 100 μL of blood was taken from the femoral vein 11 and 13 days after the injection of the prostaglandin F2 alpha analog cloprostenol (Cloprostenol C; Fujita Pharmaceuticals Inc., Tokyo, Japan), and plasma progesterone concentrations were measured with an enzyme immunoassay (AIA-360; Tosoh Corp., Tokyo, Japan). In common marmoset, the peripheral blood progesterone concentrations in follicular phase of the ovarian cycle is <10 ng/mL and those in luteal phase is >10 ng/mL [12] . The day of ovulation (Day 0) was designated as the day prior to the increase of progesterone concentrations from basal levels to >10 ng/mL. Animals were subjected to embryo collection on days 4-7 and embryo transfer on days 2-5. Embryo collection and transfer were performed using nonsurgical methods as previously described [13, 14] . Briefly, for embryo collection, a blunt tapered 28-G inner stainless steel cannula and a blunt tapered 19-G outer stainless steel cannula were inserted into the uterus with the aid of ultrasonography. While compressing the oviducts, 4 mL of flushing medium was injected through the inner cannula into the uterus. The perfused medium was collected in a dish as it dripped from the outer cannula. For embryo transfer, one or two embryos were transferred into the uterus of each surrogate mother using the same technique as for embryo collection. After embryo transfer, the recipients were monitored for pregnancy by ultrasound imaging once a month until delivery.
Establishment of ear fibroblasts from infant transgenic marmosets
A small piece of ear tissue was washed three times in phosphatebuffered saline (PBS) and minced by scissors, followed by incubation in PBS containing 1 mg/mL collagenase (034-22363, Wako, Tokyo, Japan) for 30 min at 37
• C. Cells were washed twice by centrifugation and cultured in Dulbecco Modified Eagle Medium (043-30085, Wako, Tokyo, Japan) containing 10% fetal bovine serum (GIBCO).
Doxycycline-inducible transgene expression in the ear fibroblasts of founder (F0) marmosets
To examine inducible transgene expression by the tet-on system, fibroblasts collected from F0 marmosets were treated with 10 μg/mL doxycycline (D9891, Sigma-Aldrich, Germany) for 3 days. After treatment, the fibroblasts underwent RNA extraction and real-time PCR analysis.
Doxycycline-inducible transgene expression in F0 transgenic marmosets
To induce transgene expression at the individual level, F0 marmosets were treated with 2 mg/mL doxycycline in drinking water for 10 days. Blood (200 μL) from transgenic marmosets was collected before and after doxycycline treatment, and subjected to RNA extraction and real-time PCR analysis.
DNA/RNA extraction from fibroblast cell and blood and reverse transcription DNA/RNA was isolated from fibroblasts using the AllPrep DNA/RNA mini kit (80004, QIAGEN, USA), and RNA was isolated from blood using the QIAamp RNA blood Mini Kit (52304, QIAGEN) according to the manufacturer's instructions. First-strand cDNA was synthesized from RNA using the ReverTra Ace qPCR RT Master Mix with gDNA Remover (FSQ-301, TOYOBO, Osaka, Japan). As a negative control, RNA was reacted with the cDNA synthesis reaction mixture in the absence of reverse transcriptase.
Polymerase chain reaction (PCR) analysis
To detect the mutant ataxin 3 transgene, TRE-Fwd (5 -GCCCTTTCGTCTTCAATCGAG-3 ) and PQ120-Rev (5 -TGTTGAGCACAAAGTGAGCCTTC-3 ) primers were used for amplification. To detect the β-actin gene for reference gene, ACTB-Fwd1 (5 -AACTGGGACGACATGGAGAAGATC-3 ) and ACTB-Rev2 (5 -GTAGCACAGCTTCTCCTTGATGTC-3 ) primers were used. Genomic DNA and cDNA underwent PCR amplification involving 40 cycles of 98
• C for 10 s, 64
• C for 30 s, and 72
• C for 30 s using the EmeraldAmp PCR Master Mix (RR300A, Takara, Shiga, Japan) according to the manufacturer's instructions.
DNA extraction from fingernails and PCR analysis
The fingernails were collected from founder marmosets according to previous report [15] . Briefly, approximately 2-or 1.5-mm fingernail fragments were clipped from the finger claw and dipped in a 100 μL aliquot of 50 mM NaOH, followed by boiling at 95
• C for 30 min.
Then, 10 μL of 1 M Tris-HCl (pH 8.0) was added and mixed. This crude underwent PCR amplification involving 40 cycles of 98 • C for 10 s, 64
• C for 30 s, and 68
• C for 60 s using the KOD FX Neo (KFX201, TOYOBO) according to the manufacturer's instructions.
Real-time PCR analysis
To quantify the relative expression of transgenes, PQ120-Fwd (5 -ACTTGGGAGTGATCTAGGTGATG-3 ) and HA-Rev (5 -AGTCGGGGACGTCGTAGGGGTATT-3 ) primers were used for amplification. To detect the β-actin gene for reference gene, ACTBFwd3 (5 -GATGGTGGGCATGGGTCAGAA-3 ) and ACTB-Rev4 (5 -AGCCACACGCAGCTCGTTGT-3 ) primers were used. Complementary DNA was subjected to real-time PCR for 45 cycles of 98 • C for 10 s, 64
• C for 30 s using FastStart
Essential DNA Green Master (06402712001, Roche, Schweiz) and the LightCycler Nano system (06407773001, Roche) according to the manufacturer's instructions. All real-time PCR results were normalized with β-actin, and the relative transgene expression levels were analyzed using ct method. The transgene expression level in fibroblasts and blood of TET1 without doxycycline treatment was set as 1. Statistical analysis was performed using Tukey multiple comparisons test, with statistical significance set at P < 0.05.
Production of second-generation (F1) transgenic marmosets by intracytoplasmic sperm injection using cryopreserved TET1 sperm F1 transgenic marmoset embryos were produced as described previously [16, 17] . Briefly, TET1 was restrained in an upright position and induced to ejaculate using a vibrator using a FertiCare personal vibrator (Fertility Healthcare and Supplies, Inc., Silverado, CA, USA), and the semen was collected in 500 μL of TYH medium (DR01031, LSI Medience Corp., Tokyo, Japan). Immediately after collection, an aliquot of semen was washed twice by centrifugation in TYH medium, and sperm was suspended in 300 μL of TYH medium, cooled to 4
• C for 30 min, followed by the addition of equal volumes of sperm freezing medium (10670010, ORIGIO). A sperm aliquot was cryopreserved in liquid nitrogen according to the manufacturer's instructions. Germinal vesicle-stage oocytes of wild-type marmosets were retrieved from follicles (500 μm in diameter) by puncture and cultured for 30 h in porcine oocyte medium [18] (335-00661, Wako) supplemented with 100 mIU/mL of human recombinant follicle-stimulating hormone (Follitropin beta, 2413405G1026, MSD Corp., Tokyo, Japan). Mature oocytes were fertilized with frozen-thawed TET1 sperm in M2 medium by intracytoplasmic sperm injection (ICSI) using a micromanipulator (Narishige, Tokyo, Japan) with the PiezoDrive system (Primetech Corp., Tokyo, Japan). The resultant fertilized embryos were activated by electrical stimulation as described previously [19] . Briefly, 3 h after ICSI, embryos were placed between the electrodes of a fusion chamber filled with 0.28 M mannitol containing 0.1 mM MgSO 4 , 0.1 mM CaCl 2 , and 0.1 mg/mL polyvinyl alcohol. They were then exposed to 2 DC pulses of 100 V/mm for 99 μs at intervals of 1 s, followed by culturing in TYH medium. On the following day, the embryos were transferred to surrogate mothers.
Results
Production of F0 transgenic marmosets
A high-titer lentiviral vector carrying TRE-ataxin 3-120Q-CMV-KO-2A-rtTA ( Figure 1A ) was injected into 34 embryos of 4-to 16-cell stage, then embryo transfer to 18 surrogate mothers was performed (Table 1) . A total of nine surrogates became pregnant, of which eight delivered a total of 12 offspring. Five of the 12 offspring were stillborn because of obstruction in the birth canal; the remaining Table 1 . Production rates of F0 marmosets. A high-titer lentiviral vector was injected into a total of 34 embryos, followed by embryo transfer to 18 surrogate mothers. A total of nine surrogates became pregnant, and eight surrogates delivered 12 offspring. seven marmosets were named TET1-7. The littermates were TET1 and 2, 3 and 4, and 6 and a stillborn marmoset.
TRE-ataxin 3-120Q-CMV-KO-
Analyses of transgene integration and inducible transgene expression in F0 marmosets
Transgene integration was confirmed in four out of seven offspring, TET1, 3, 4, and 6, by PCR amplification using genomic DNA collected from ear fibroblasts ( Figure 1B) . Moreover, the fingernail PCR was performed to distinguish the transgenic and blood chimera offspring that is peculiar to marmosets. As shown in Figure 1B , the results in fingernail were consistent with those in fibroblasts, showing that TET1, 3, 4, and 6 were transgenic. While, two different lengths of PCR products were detected in the TET1 genome, suggesting the possibility of a deletion in the TRE sequence in several fibroblasts. To examine transgene expression controlled by the tet-on system, fibroblasts cultured with or without doxycycline were subjected to quantitative real-time PCR analyses. As shown in Figure 1C , transgene expression was detected in the fibroblasts of TET1 and 3, but not in those of TET4 and 6. The transgene expression of fibroblasts from TET1 and 3 increased 3.4-and 1.4-fold, respectively, after doxycycline treatment ( Figure 1C) . To determine the functionality of the tet-on system at the individual level, F0 marmosets were given drinking water containing 2 mg/mL doxycycline for 10 days. As shown in Figure 1D , transgene expression was detected in the blood of TET1, 2, 3, 4, and 6, and the transgene expression level of each marmoset increased by 1.7-, 3.2-, 1.8-, 1.6-, and 1.1-fold, respectively, after exposure to doxycycline. Considering that the absence of transgene in the genome of ear fibroblasts and fingernails, TET2 was blood chimera marmoset.
Production of F1 transgenic marmosets from TET1 (male)
To obtain F1 transgenic marmosets, ejaculated sperm from TET1 was collected and cryopreserved after he had reached sexual maturity at the age of 11 months. In our method, there were very few motile sperm after thawing (Supplementary Figure S1) ; therefore, frozen-thawed sperm was injected into the oocytes of a wild-type marmoset by ICSI. A total of six embryos were transferred to three surrogate mothers, all of which became pregnant and delivered a total of four offspring (Table 2) . However, three of the four offspring were stillborn because of obstruction in the birth canal; the remaining offspring survived and was named TET1-1. Two of the Table 2 . Production rates of F1 marmosets from TET1. -1-1-3) , a positive control (Plasmid), and negative controls (Wild type and Water); (B) Sequence analysis of the TRE region in TET1 and TET1-3 marmosets. Underbar ( ), square ( ), hyphen (-), and asterisk ( * ) indicate tetO sequence, mutation, deletion, and ataxin 3 coding region, respectively.
three dead offspring were collected and named TET1-2 and 1-3. PCR analysis detected the mutant ataxin 3 transgene in TET1-2 and 1-3, but not in TET1-1 (Figure 2A ), while the lower lengths of PCR products were detected in the TET1-3 genome. The lower lengths of PCR products from TET1 and TET1-3 underwent sequencing analysis, which detected a point mutation of thymine to adenine in the fourth tetO sequence, and a 72 bp deletion from the fourth to the sixth tetO sequence in both TET1 and TET1-3 ( Figure 2B ).
Production of F1 offspring from TET3 (female)
A total of six F1 offspring from TET3 were obtained from two deliveries by natural mating, and named TET3-1-3-6. TET3-1 and TET3-2 were from the first delivery, and TET3-3-TET3-6 were from the second delivery. Five (TET3-1-TET3-5) were live offspring, while TET3-6 was stillborn. PCR analysis revealed that the transgene was detected only in TET3-3 ( Figure 3A ). To examine transgene expression controlled by the tet-on system, fibroblasts cultured with or without doxycycline underwent quantitative real-time PCR analyses. As shown in Figure 3B , transgene expression in fibroblasts from TET3-3 was almost at the same level as in TET3, and increased 1.5-fold after doxycycline treatment ( Figure 1C ).
Discussion
Most studies using genetically modified animals have been performed in mice because gene modification techniques using embryonic stem cells are well established in this species. Such techniques are less advanced in nonhuman primates because of an absence of embryonic stem cells with germline transmission capacity. In the present study, we used lentivirus-mediated gene transfer, which has been used successfully to generate transgenic nonhuman primates [20] and is currently accepted to generate transgenic marmosets with germline transmission [21, 22] . Our transgenic marmosets expressed the mutant human ataxin 3 gene, and to our knowledge this is the first report of nonhuman primates carrying a transgene under the control of the tet-on system, artificially induced by doxycycline administration via drinking water. In our previous study, transgenic marmosets carrying the mutant ataxin 3 gene under the control of the CMV promoter showed high abortion rates in the early gestation period, juvenile disease onset, and rapid disease progression; therefore, F1 offspring were difficult to obtain [3] . Compared with these, the production rates of F0 marmosets in the present study were increased (10.6% vs. 35.3%, respectively) because of reduced fetal death in the early gestation period. Moreover, a live F1 transgenic marmoset was obtained from TET3 by natural mating because juvenile disease onset was not observed in all F0 transgenic marmosets. Doxycycline-inducible transgene expression in fibroblasts from F1 offspring showed that TET3-3 maintained a high transgene expression level that matched its parent (TET3). Given that germline transmission and transgene expression were confirmed in our transgenic marmosets, induced disease onset experiments by doxycycline administration are future challenges in F1 or later generations. While the apparent increase in stillbirths after full-term development was observed in the present study. We think this is due to the fact that we used young primipara marmosets as surrogate mothers because the primipara marmosets in the colony for natural mating often miscarry their first offspring by obstruction in the birth canal.
Several F0 marmosets showed different transgene expression patterns between fibroblasts and blood. Despite the absence of transgene expression in ear fibroblasts, it was expressed in the blood of TET2, 4, and 6. Considering that TET2 was not transgenic, this appears to reflect the blood chimerism peculiar to marmosets. Marmosets are natural blood chimeras, a condition that results from the high frequency of fraternal twinning and the consistent development of placental vascular anastomoses between the two embryos [23, 24] . In the present study, TET1 and 2, 3 and 4, 6 and the stillborn marmoset were respective littermates, and TET1, 3, and the stillborn marmoset (data not shown) were transgenic. Therefore, TET2 was a blood chimera but not a transgenic. While, TET4 and 6 were transgenic, but there is a possibility of blood chimerism.
Transgenesis achieved using pronuclear microinjection or virus infection is often associated with somatic and germline mosaicism in F0 transgenic animals [25, 26] . In our study, the mutated transgene was observed in the genomic DNA of TET1, while its offspring inherited both intact and mutated transgenes, showing that TET1 was mosaic in somatic and germline cells. DNA sequence analysis revealed that the mutated transgene in TET1 and TET1-3 contained a single nucleotide mutation and a 72 bp deletion in the TRE region ( Figure 2B ). The TRE sequence used in the present study consisted of seven repeats of the tetO sequence separated by spacer sequences; therefore, it might be susceptible to mutation. The fact that a mutation and deletion were observed in our transgenic marmosets indicates the likelihood of these occurring frequently in the transgenesis of nonhuman primates using the tet-on system. The relatively modest fold-induction of transgene expressions were observed in the fibroblasts and the animals treated with doxycycline. We think this was due to the transgene silencing. The CMV promoter is known to be susceptible to gene silencing in mammalian cells [27] , and the construct of TRE-ataxin 3-120Q-CMV-KO-2A-rtTA has two CMV promoter sequences. The ataxin 3 was driven by minimal CMV promoter in TRE [28] and rtTA was also driven by CMV promoter; therefore, we think that the resultant fold-induction of transgene expressions was reduced by transgene silencing.
Little is known about the predictive diagnosis of neurodegeneration because neurodegenerative diseases are difficult to detect presymptomatically. The tetracycline-controllable gene expression system will enable us to distinguish phenotypes and molecular biology before and after disease onset. In mice models of neurodegenerative disease, the tetracycline-controllable gene expression system demonstrated that both neurological and physiological symptoms are reversible [10, 11] , and that reducing the production of pathogenic proteins may be a promising approach to treat neurodegenerative diseases. However, they neither represent the selective vulnerability of specific neurons or circuits in their short lifetime nor provide us with precise imaging diagnosis because of their small brain size. Therefore, the availability of clinically relevant transgenic nonhuman primate models of neurodegenerative disease is imperative to clarify our understanding of disease onset and progression. The marmoset, in particular, offers many advantages regarding reproductive features and small body size, and is nonendangered. It reaches sexual maturity at around 1 year of age, has a short gestation period, and yields multiple offspring per delivery. Its small body size also enables us to handle it with ease, which translates into lower caging and feeding costs. Furthermore, several transgenic animals with transgene germline transmission [3, 21, 22] have been rapidly established in the last decade. Therefore, our transgenic marmoset carrying a novel transgene expression system will be useful for studies on neurodegenerative diseases, including the identification of disease biomarkers and evaluation of the efficacy and metabolic profiles of therapeutic candidates.
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Supplementary Figure S1 . Several motility indexes in prefreezing and post thawing sperm. Semen was collected from wild-type adult marmoset using a vibrator. Several motility indexes (rate of motility sperm, linear velocity, and vibration frequency of sperm head per second) in prefreezing and postthawing sperm were analyzed by sperm motility analysis system (SMAS; DITECT Co. Ltd, Tokyo, Japan), which is one of the computer-assisted sperm analysis (CASA) system. All indexes significantly decreased in frozen-thawed sperm and there were very few motile sperms after thawing objectively.
